GSK inks $231M man­u­fac­tur­ing deal as Hal Bar­ron an­tic­i­pates fruit­ful year for pruned R&D group

Al­most halfway in­to the big turn­around year that Hal Bar­ron has blue­print­ed for Glax­o­SmithK­line’s R&D team, the Big Phar­ma is un­veil­ing a $231 mil­lion man­u­fac­tur­ing deal to match the grow­ing com­mer­cial port­fo­lio.

In a new part­ner­ship, GSK has en­list­ed Sam­sung Bi­o­log­ics to pro­vide ad­di­tion­al man­u­fac­tur­ing ca­pac­i­ty for its com­mer­cial spe­cial­ty care drugs, be­gin­ning with the lu­pus drug Benlysta. Pro­duc­tion will take place in Sam­sung’s fa­cil­i­ties in Ko­rea, the com­pa­ny told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER